Compare PRVA & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | TMDX |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2021 | 2019 |
| Metric | PRVA | TMDX |
|---|---|---|
| Price | $20.48 | $67.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | $31.17 | ★ $148.22 |
| AVG Volume (30 Days) | 915.5K | ★ 1.9M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.64 | ★ 382.18 |
| EPS | 0.02 | ★ 0.20 |
| Revenue | ★ $2,122,842,000.00 | $605,494,000.00 |
| Revenue This Year | $18.19 | $24.25 |
| Revenue Next Year | $10.72 | $18.75 |
| P/E Ratio | $1,040.00 | ★ $342.25 |
| Revenue Growth | 22.26 | ★ 37.13 |
| 52 Week Low | $18.78 | $60.11 |
| 52 Week High | $26.51 | $156.00 |
| Indicator | PRVA | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 33.95 |
| Support Level | $19.53 | $60.11 |
| Resistance Level | $24.09 | $71.14 |
| Average True Range (ATR) | 0.65 | 3.63 |
| MACD | -0.27 | 1.63 |
| Stochastic Oscillator | 2.78 | 66.12 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.